ADMA (ADMA) Q1 2026 Earnings Transcript

ADMA Biologics reported Q1 revenue of $114.5 million, roughly flat year over year, but delivered strong profitability with gross margin expanding to 71% from 53% and adjusted EBITDA rising 24% to $59.7 million. ASCENIV revenue surged 28% to $97.5 million, offsetting a 54% decline in BIVIGAM amid intense competition and channel inventory disruption, while management raised full-year 2026 guidance and withdrew long-term guidance due to market uncertainty. Cash from operations reached $58 million, net leverage stayed below 0.5x, and the company continued buybacks and plasma-center monetization.

Analysis

ADMA is in the rare phase where a company can look operationally “messy” at the revenue line while the economics are quietly improving underneath. The mix shift toward ASCENIV is not just a margin tailwind; it’s a moat-expansion event, because the product’s demand appears less price-elastic than standard IG and is being reinforced by real-world evidence, pediatric expansion, and specialty distribution penetration. If that holds, the market is likely underestimating how much of 2026-2027 earnings can be insulated from the broader IG price war.

The real second-order winner here may be MCK. A large distributor with specialty reach and lower DSO characteristics can become structurally more important when smaller suppliers are fighting for shelf space and working capital efficiency matters more than gross billing growth. That should also pressure weaker IG players that rely on aggressive discounting: once inventories normalize, the companies with the most levered channel strategies may have to choose between defending share and defending price, and neither outcome is great for long-term ROIC.

The main risk is that management’s “transitory” framing proves too optimistic: channel inventory digestion can last multiple quarters, and pricing resets in biologics often overshoot before stabilizing. The withdrawal of long-term guidance is important—not because the story is broken, but because visibility on the standard IG market just fell sharply, which widens the distribution of outcomes. In the next 1-2 quarters, the key tell will be whether ASCENIV growth is truly channel-agnostic or whether it eventually inherits the same rebate/ordering pressure now hitting BIVIGAM.

Consensus is likely over-focusing on the headline revenue deceleration and underpricing the balance sheet optionality. With leverage near zero, strong cash generation, and buybacks still active, ADMA has unusually cheap internal funding for SG-01 and commercial expansion; that lowers dilution risk and raises the value of execution. If April is representative, the stock may rerate on sequential evidence before consensus has time to rebuild a long-term model, making this a classic “show-me” setup rather than a broken growth story.

Key Decisions for Investors

• Long ADMA common into the next 4-8 weeks on confirmation of sequential ASCENIV acceleration; target a rerating if the market starts to discount Q2 as the revenue inflection quarter. Risk: if channel inventory persists, the stock can stay range-bound despite strong EBITDA.
• Buy ADMA call spreads 3-6 months out rather than outright calls to express upside from margin/cash-flow resilience while limiting downside if guidance remains noisy. Prefer strikes that monetize a modest rerating rather than a full growth revaluation.
• Pair trade: long ADMA / short a basket of standard IG or plasma names with higher exposure to discounting and working-capital strain. The thesis is that ADMA’s differentiated product mix and balance sheet make it a relative winner in an oversupplied channel.
• Add MCK on pullbacks as a quieter beneficiary of specialty distribution share gains and improved DSO behavior across customers using its network. Time horizon: 6-12 months, with lower volatility than the biotech leg.
• Avoid chasing companies in standard IG that are still competing primarily on price; if channel normalization takes longer than expected, those names face margin compression before volume recovers.